Cross-Sector entity
clinical-trial is the sole category represented across all 1 tracked stories. NUZ-001 is most often covered alongside Massachusetts General Hospital, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention NUZ-001, all published on February 26, 2026.
1 verified story tracked
Last mentioned: Feb 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. NUZ-001 is most often covered alongside Massachusetts General Hospital, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention NUZ-001, all published on February 26, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NUZ-001. Shared-story counts are live from our verified record — not editorial picks.
Interim Analysis
Expected window for preliminary safety and biomarker data review by the trial committee.
Dosing Initiation
First patient dosed with NUZ-001 in the multi-center Phase 2/3 study.
Trial Selection
NUZ-001 selected as a new regimen for the HEALEY ALS Platform Trial.
Neurizon has officially commenced patient dosing for NUZ-001 in the HEALEY ALS Platform Trial, a multi-center study led by Massachusetts General Hospital. This milestone marks a critical transition for the biotech as it seeks to validate its mTOR inhibitor as a disease-modifying therapy for Amyotrophic Lateral Sclerosis.
Source: sydneysun.com · malaysiasun.com
